Selank

Common questions about Selank

What is Selank?

Selank is a synthetic heptapeptide derived from the immune-modulator tuftsin (TP-7). It is studied in Russian neuropharmacology research for anxiolytic and nootropic effects, and is one of the most-cited synthetic neuropeptides in that tradition alongside Semax.

Is Selank FDA-approved?

No. Selank is not approved by the FDA, MHRA, Health Canada, or the TGA. It has been used clinically in Russia under the regulatory framework of the Russian Federation, but it is sold by Western research-peptide vendors strictly as a research compound.

What is the half-life of Selank?

Pepticker does not publish a quantitative plasma half-life for Selank — published Russian pharmacokinetic data are not as readily available as for prescription peptides, and ranges reported in the literature vary by route and assay method.

What dose of Selank is used in research?

Doses reported in published Russian neuropharmacology studies vary by route (intranasal vs. parenteral) and endpoint. Pepticker does not publish a dosing protocol — refer to the original literature for the model you are reproducing.

What is Selank commonly stacked with?

Selank is most often discussed alongside Semax in the published Russian neuropeptide literature, with researchers studying combined or sequential protocols across anxiolytic and nootropic endpoints.

Is Selank legal?

Selank is sold for research use in the US, Canada, and the UK. In Australia it is TGA Schedule 4 and personal import is tightly controlled. Status is informational — not legal advice.

Editorial summary of published research. Not medical advice. See /methodology for sourcing.